Our investment goal is to generate attractive risk-adjusted return streams by systematically identifying market anomalies through the judicious combination of art & science.
With a $50 million inaugural fund, we focus on seed and Series A investments in ambitious technology startups across sectors like enterprise software, fintech, and healthcare tech.
